Almanack Investment Partners’s Gilead Sciences GILD Stock Holding History

Almanack Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,202	Closed	-$198K	–	566
2022 Q3	$198K	Buy	+3,202	New	+$202K	0.04%	134
2021 Q2	–	Sell	-4,452	Closed	-$288K	–	462
2021 Q1	$288K	Buy	4,452 +926	+26%	+$59.7K	0.03%	320
2020 Q4	$205K	Buy	+3,526	New	+$213K	0.02%	353
2018 Q2	–	Sell	-2,820	Closed	-$213K	–	158
2018 Q1	$213K	Buy	2,820 +604	+27%	+$48K	0.08%	103
2017 Q4	$159K	Buy	2,216 +119	+6%	+$9.04K	0.06%	140
2017 Q3	$170K	Buy	+2,097	New	+$160K	0.08%	106

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Almanack Investment Partners's GILD Position: Q4 2022 in Review

Almanack Investment Partners sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 3,202 shares — an estimated $198K sold.

Almanack Investment Partners first reported a position in GILD in Q3 2017 and held it in 6 quarters. The position peaked at $288K in Q1 2021. 1,768 funds tracked by Wall St. Rank hold GILD as of Q4 2022.

Almanack Investment Partners reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
Almanack Investment Partners sold 3,202 Gilead Sciences shares in Q4 2022, an estimated $198K.
Almanack Investment Partners first reported a position in Gilead Sciences in Q3 2017 and held it in 6 quarters.
Almanack Investment Partners's Gilead Sciences position peaked at $288K in Q1 2021.
1,768 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.